According to the Associated Press, Johnson & Johnson’s artificial joint company, DePuy Orthopaedics Inc., has recalled two hip replacement products: the ASR Hip Resurfacing System and the ASR XL Acetabular System. Data from the National Joint Registry of England and Wales reveals that corrective surgery has been necessary within five years of the initial surgery for approximately 12% of people who have received the hip resurfacing system and for about 13% of individuals who have received the acetabular system. These results amount to one in eight patients requiring revision hip replacement surgery.
Some patients who have received the DePuy artificial joint implants have experienced pain and difficulty walking. Each of the metal hip replacement products are meant to restore worn or weakened parts of the hip, more specifically the socket at the outer portion of the pelvis and the rounded bone on top of the thigh bone that fits into the socket. A complete hip replacement replaces both parts simultaneously. The ASR XL Acetabular System (total hip replacement) was advertised as having several advantages over both conventional hip replacements and hip resurfacing (ASR Hip Resurfacing System) since it became available in 2005. Both ASR products have been discontinued by DePuy.
The defective hip replacement implant lawyers at Panish Shea & Boyle LLP are currently investigating claims for those who have been injured due to the failure of their hip replacement systems. If you or a loved one have a DePuy ASR hip replacement or hip resurfacing system and have experienced adverse effects, please contact one of our skilled medical product liability lawyers. You have a limited amount of time to file legal action against DePuy for a failed ASR hip system. Call Panish Shea & Boyle LLP today at 877-800-1700 for a free consultation.
A Reuters article reports that Johnson & Johnson has recalled four additional lots of Benadryl allergy medications and one lot of Extra Strength Tylenol gels. In following-up on its larger recall of over the counter drugs on January 15, Johnson & Johnson announced that it unintentionally failed to include the most recent medications in the previous product defects recall.
After several consumer complaints of musty or moldy odors earlier this year, Johnson & Johnson recalled 53 million bottles of a variety of products including Tylenol and Motrin painkillers, Rolaids, Benadryl and St. Joseph’s Aspirin.
With the new lots of recalled J&J medications included, the company has issued four product recalls within the last year due to quality control problems at its plants. In order to determine the reasons for these issues and to ensure that other problems are not being overlooked, a Congressional investigation has been initiated in addition to continuous examination by the U.S. Food and Drug Administration.
The Chairman of the U.S. House of Representatives Oversight and government Reform Committee, Edolphus Towns, stated, “This latest recall is further evidence that there are wide-ranging problems at Johnson & Johnson.”
While Johnson & Johnson contends that the danger of severe adverse medical events from the recalled medication is remote, consumers in possession of any of the recalled lots are advised to stop use and dispose of the medications.
Prescription and over the counter drugs are intended to alleviate an illness or condition, not create new health problems. In some cases, by the time a drug recall is announced, innocent consumers have already suffered harm as a result of the recalled medication. The California pharmaceutical litigation attorneys at Panish Shea & Boyle LLP have achieved successful case results for individuals who have been adversely affected by contaminated drugs and other consumer products. Contact us today by calling 877-800-1700 for a free consultation of your products liability case.
